Please ensure Javascript is enabled for purposes of website accessibility

FDA Postpones All Foreign Inspections Over Coronavirus

By Mark Prvulovic - Mar 10, 2020 at 8:50PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The agency said it is suspending all non-U.S. inspections effective immediately.

As the ongoing COVID-19 outbreak continues to worsen, the U.S. Food and Drug Administration (FDA) announced that it will postpone all foreign inspections, effective immediately.

The agency said it won't conduct inspections of foreign manufacturing facilities until the end of April. However, inspections outside the country that are designated "mission-critical" will still be considered on a case-by-case basis.

A red umbrella protecting several men in suits from a virus.

Image source: Getty Images.

"We are aware of how this action may impact other FDA responsibilities, including product application reviews," the agency said in a statement. "We will be vigilant and monitor the situation very closely and will try to mitigate potential impacts from this outbreak in lockstep with the whole of the federal government."

Although the FDA promises to resume inspections as soon as possible, there's a strong possibility that it could extend this inspection halt well past April if the outbreak gets worse.

Further details

The total number of COVID-19 cases has grown to over 118,000, with almost 4,300 deaths so far. Although the growth rate of infections in China has slowed down drastically, other countries, such as Italy, Iran, and Korea, have all seen an alarming explosion of cases over the past couple of weeks.

There are a number of biotech companies working on a treatment, including Gilead Sciences (GILD 1.08%) with its antiviral drug remdesivir and Moderna's mRNA-based vaccine. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Gilead Sciences, Inc. Stock Quote
Gilead Sciences, Inc.
GILD
$64.35 (1.08%) $0.69

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
334%
 
S&P 500 Returns
117%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.